IQV Stock Forecast 2025-2026
Distance to IQV Price Targets
IQV Price Momentum
10 Quality Stocks Worth Considering Now
Researching IQVIA (IQV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IQV and similar high-potential opportunities.
Latest IQV Stock Price Targets & Analyst Predictions
Based on our analysis of 41 Wall Street analysts, IQV has a bullish consensus with a median price target of $250.00 (ranging from $205.00 to $270.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $180.02, the median forecast implies a 38.9% upside. This outlook is supported by 21 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sean Dodge at RBC Capital, projecting a 50.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IQV Analyst Ratings
IQV Price Target Range
Latest IQV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IQV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2025 | Citigroup | Patrick Donnelly | Neutral | Maintains | $210.00 |
| Feb 18, 2025 | JP Morgan | Anne Samuel | Overweight | Maintains | $232.00 |
| Feb 11, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $250.00 |
| Feb 10, 2025 | Truist Securities | Jailendra Singh | Buy | Reiterates | $263.00 |
| Feb 10, 2025 | RBC Capital | Sean Dodge | Outperform | Reiterates | $270.00 |
| Feb 7, 2025 | UBS | Dan Leonard | Buy | Maintains | $255.00 |
| Feb 7, 2025 | Stifel | Shlomo Rosenbaum | Buy | Maintains | $261.00 |
| Feb 3, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $235.00 |
| Jan 21, 2025 | Baird | Eric Coldwell | Neutral | Maintains | $210.00 |
| Dec 20, 2024 | Stephens & Co. | Jeff Garro | Overweight | Initiates | $250.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $235.00 |
| Dec 12, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $261.00 |
| Dec 11, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $270.00 |
| Dec 11, 2024 | Baird | Eric Coldwell | Neutral | Maintains | $212.00 |
| Dec 4, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $270.00 |
| Nov 19, 2024 | Leerink Partners | Michael Cherny | Outperform | Reiterates | $248.00 |
| Nov 5, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $270.00 |
| Nov 5, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $240.00 |
| Nov 4, 2024 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $265.00 |
| Nov 4, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $265.00 |
Iqvia Holdings Inc. (IQV) Competitors
The following stocks are similar to IQVIA based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iqvia Holdings Inc. (IQV) Financial Data
Iqvia Holdings Inc. has a market capitalization of $31.74B with a P/E ratio of 24.0x. The company generates $15.40B in trailing twelve-month revenue with a 8.9% profit margin.
Revenue growth is +2.3% quarter-over-quarter, while maintaining an operating margin of +16.0% and return on equity of +22.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Iqvia Holdings Inc. (IQV) Business Model
About Iqvia Holdings Inc.
Provides analytics and technology solutions for healthcare.
Iqvia generates revenue by offering advanced analytics, technology solutions, and contract research services primarily to the pharmaceutical, biotechnology, and medical device industries. The company supports drug development through clinical research and regulatory services, while its technology solutions utilize AI and machine learning to enhance operations and patient outcomes.
With a vast data repository and innovative analytical platforms, Iqvia is recognized as a key partner in the healthcare sector, helping organizations adapt to complex regulatory environments and accelerate innovation in drug development.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
88,000
CEO
Mr. Ari Bousbib
Country
United States
IPO Year
2013
Website
www.iqvia.comIqvia Holdings Inc. (IQV) Latest News & Analysis
IQVIA (NYSE:IQV) has been recognized in the "Leaders" category of the IDC MarketScape for its decentralized clinical trial technology solutions and consulting services in 2024.
IQVIA's recognition as a leader in decentralized clinical trial technology enhances its market credibility, potentially boosting investor confidence and attracting new business opportunities.
IQV stock is bolstered by its global healthcare IT infrastructure and extensive data resources, providing a competitive edge in the market.
IQV's strong healthcare IT infrastructure and extensive data assets enhance its competitive edge, likely leading to better growth prospects and potentially higher stock performance.
IQVIA Laboratories has launched Site Lab Navigator, a solution to automate lab workflows for clinical trials, featuring an e-Requisition system for managing lab specimens electronically.
The launch of Site Lab Navigator enhances efficiency in clinical trials, potentially reducing costs and time for drug development, which may positively impact IQVIA's market position and financial performance.
Zacks Style Scores can help investors select strong, market-beating stocks for their portfolios.
Zacks Style Scores provide a systematic approach to identify high-potential stocks, aiding investors in making informed decisions for better returns.
IQVIA (NYSE:IQV) announced its AI Assistant won a 2024 PM360 Innovation Award in AI. Launched in September 2024, it enhances insight generation for life sciences and healthcare.
IQVIA's AI Assistant innovation enhances its competitive edge in the life sciences sector, potentially driving revenue growth and boosting stock performance.
A lack of adult vaccinations by pharmacists can lead to millions missing out on necessary immunizations, impacting public health and potentially affecting healthcare-related investments.
Limited access to adult vaccinations may lead to increased healthcare costs and lower productivity, affecting public health and potentially impacting healthcare stocks and related sectors.
Frequently Asked Questions About IQV Stock
What is Iqvia Holdings Inc.'s (IQV) stock forecast for 2025?
Based on our analysis of 41 Wall Street analysts, Iqvia Holdings Inc. (IQV) has a median price target of $250.00. The highest price target is $270.00 and the lowest is $205.00.
Is IQV stock a good investment in 2025?
According to current analyst ratings, IQV has 21 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $180.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IQV stock?
Wall Street analysts predict IQV stock could reach $250.00 in the next 12 months. This represents a 38.9% increase from the current price of $180.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iqvia Holdings Inc.'s business model?
Iqvia generates revenue by offering advanced analytics, technology solutions, and contract research services primarily to the pharmaceutical, biotechnology, and medical device industries. The company supports drug development through clinical research and regulatory services, while its technology solutions utilize AI and machine learning to enhance operations and patient outcomes.
What is the highest forecasted price for IQV Iqvia Holdings Inc.?
The highest price target for IQV is $270.00 from Sean Dodge at RBC Capital, which represents a 50.0% increase from the current price of $180.02.
What is the lowest forecasted price for IQV Iqvia Holdings Inc.?
The lowest price target for IQV is $205.00 from at , which represents a 13.9% increase from the current price of $180.02.
What is the overall IQV consensus from analysts for Iqvia Holdings Inc.?
The overall analyst consensus for IQV is bullish. Out of 41 Wall Street analysts, 21 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $250.00.
How accurate are IQV stock price projections?
Stock price projections, including those for Iqvia Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
